Objective: To study the clinical characteristics and prognosis of morphea in Thai adult patients. Methods: The medical records of 81 morphea adult patients who visited Siriraj Hospital, Thailand, between 2006 and 2015, were retrospectively reviewed. The demographics, clinical features, treatments and outcomes were analyzed.
INTRODUCTION
Morphea, or localized scleroderma, is a rare, chronic, autoimmune disease manifested by dermis and/or subcutaneous tissue sclerosis. 1 The incidence of morphea is approximately 2.7 cases/100,000 people. 2 Morphea is divided into five subtypes: (1) circumscribed morphea (including a superficial and deep variant); (2) linear morphea (including a limb/trunk variant and a head variant); (3) generalized morphea; (4) the pansclerotic subtype; and (5) the mixed subtype. 1 The different clinical manifestations of morphea have led to the development of different classifications and progressions of the disease. 1, 3 Therefore, this study aimed to elucidate the clinical characteristics, treatment types, results after treatment, and prognosis of adult patients with morphea.
Demographic data, clinical manifestations, lesion sites, symptoms, treatments and clinical responses at final followup were collected. A telephone survey was conducted to follow up the relapse status after the last consultation.
The clinical responses were subjectively categorized as excellent (>80%), partial (1%-80%), and no response. Serial photographs before and after treatment were evaluated for clinical response by two dermatologists. Additionally, the effects of the UVA1 dosage on the clinical responses and recurrence rates were gathered. UVA1 phototherapy was categorized as low-dose (20-40 J/cm 2 ), medium-dose (>40-80 J/cm 2 ) and high-dose (>80-120 J/cm 2 ). UVA1 phototherapy was administered three to five times a week for 30 sessions.
Statistical analysis
Descriptive statistics, including frequency counts and tables, were used for demographic data, clinical manifestations, clinical responses, treatments, and disease recurrence. A Chi-square test or, if there were <5 responses in a cell, a Fisher exact test was used to examine the differences in the proportions and the association strength between the clinical response and disease recurrence, according to the treatment types and UVA1-phototherapy doses. A p value of less than .05 was set as the cutoff for statistical significance. All analyses were performed using IBM SPSS Statistics for Windows, version 22.0 (IBM Corp., Armonk, N.Y., USA).
RESULTS
A total of 81 patients, aged 18-83 years and with a median age of 34 years, were included in the analysis. There were 64 (79%) females, and 17 (21%) males, making the female to male ratio 3.8:1. The median time between the initial disease manifestation and diagnosis was one month. The most common subtype of morphea was circumscribed morphea (34, 42%), followed by linear morphea (21, 26%), generalized morphea (14, 17%), en coup de sabre (11, 14%), and Parry-Romberg syndrome (1, 1%).
Morphea lesion was mostly found in the lower extremities, followed by the trunk, head and neck, and upper extremities. In circumscribed morphea, lesions were mostly found in the trunk. However, in the linear and generalized groups, lesions were mostly found in the lower extremities. Skin discoloration (79%), induration (43%) and atrophy (39%) were the top three, most common clinical symptoms of all of the types of morphea. None of the patients progressed to systemic sclerosis during the follow-up period.
The combination therapy was the most often used treatment for generalized morphea and linear morphea ( Table 1) . Topical corticosteroids (41%) were the most frequently prescribed topical treatment, followed by combined topical corticosteroids with a calcineurin inhibitor (24%), and then by a calcineurin inhibitor alone (11%). In the case of systemic treatment, colchicine (23%), corticosteroid (19%), and methotrexate (14%) were the top three prescribed medicines. Colchicine was the most commonly prescribed drug for systemic treatment in the circumscribed and en coup de sabre groups. As for linear and generalized morphea, oral prednisolone (23.8%) and methotrexate (35.7%) were the most used drugs, respectively. Fifty-nine percent of patients achieved a partial clinical response, another 18% had no response, while 9% had an excellent response. Generalized morphea (Fig 1) displayed the most favorable response rate at 79%, followed by circumscribed morphea (70%), linear morphea (67%), and en coup de sabre (46%). The linear group had the shortest recurrence time, at 8 months, followed by en coup de sabre (10 months) and generalized (31 months). Circumscribed morphea had the longest recurrence time, at 47 months.
UVA1 phototherapy was administered in 24 (30%) cases. Eighteen (75%) patients received a medium dose (>40-80 J/cm 2 ) regimen of UVA1 (Table 1 ). For all types of morphea, the clinical responses did not differ significantly with different doses of UVA1 (p=0.490; Table 2 ). UVA1 phototherapy combined with systemic treatment (oral prednisolone, methotrexate, colchicine or chloroquine) provided a significantly better response than UVA1 alone (p= 0.044). The recurrence rate did not vary significantly (p=0.674) for morphea patients treated with just UVA1 or with UVA1 plus systemic treatment. Different doses of UVA1 also had no effect on the recurrence rate (p=0.850) ( Table 2) .
The Kaplan-Meier curve demonstrated the probability of a partial to excellent clinical response for the morphea patients overall. One year after the treatment, 30% of patients achieved a partial to excellent response. After 2 years, this proportion rose to 50%. The median time to clinical response was 24 months.
DISCUSSION
This retrospective study emphasizes the clinical features and prognoses of different types of morphea. We found circumscribed morphea to be the most common type, which was similar to results from the Korea and Netherlands. 4, 5 However, a study from the United States found that generalized morphea was the most common subtype among adults. 6 17 (2, 93) median (min, max) † Other systemic treatments included chloroquine, hydroxychloroquine, isotretinoin, pentoxifylline, d-penicillamine and indomethacin ‡ UVA1 phototherapy was categorized as low dose (20-40 J/cm 2 ), medium dose (>40-80 J/cm 2 ) and high dose (>80-120 J/cm 2 ) Abbreviation: UVA1= ultraviolet A1 High dose 1 (25) 3 (75) -2 (50) † UVA1 phototherapy was categorized as low dose (20-40 J/cm 2 ), medium dose (>40-80 J/cm 2 ) and high dose (>80-120 J/cm 2 ) * p-value ≤ 0.05 considered statistically significant Abbreviation: UVA1 = ultraviolet A1 
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In the present study, clinical responses, including partial to excellent responses, were detected in 59% of the treated morphea cases. The overall level of clinical improvement was similar to the aforementioned Korean study, which showed a 63% improvement. 4 Based on the Kaplan-Meier curve, approximately 50% of treated morphea cases obtained partial to excellent clinical responses within 2 years, regardless of the treatment employed. By comparison, Mertens et al., evaluated the clinical responses after treatment with methotrexate alone; and 62% of patients show a partial to excellent response after 2 years. 7 UVA1 phototherapy is a commonly-used treatment for morphea. 8 Medium-and high-dose UVA1 phototherapy have proven to provide better outcomes for morphea than low-dose UVA1. 9 Our study showed that 80% of patients had a partial to excellent response to UVA1 (medium dose), similar to the efficacy results found in studies by Vasquez [10] [11] [12] Recurrence is common after morphea treatment. Mertens et al., reported a disease recurrence rate of 17% for adult-onset localized morphea, and 27% for pediatriconset morphea. 5 Linear morphea was the most frequent type. 5 Methotrexate combined with systemic corticosteroids showed a recurrence rate of 30%, with a 6-month mean relapse time after methotrexate discontinuation. 13 Moreover, Vasquez et al., reported a recurrence of 46% for active morphea after successful UVA1 phototherapy. 10 UVA1 phototherapy combined with immunosuppressives may inhibit episodes of recurrence. 10 Similar to another study, 10 the present study found a recurrence rate of 50% after successful treatment with UVA1. Our study supports the view that UVA1 combined with a systemic treatment for morphea provides significantly more benefits than UVA1 alone.
This study is a retrospective chart review and there was a lack of standardized criteria to evaluate the treatment responses; so the evaluation of the effectiveness of the treatments could therefore be subjective. Lastly, there may be a recall bias from the telephone interviews. We recommend a further study should be performed using validated assessments of morphea activity to reduce any bias in collecting data, such as the ultrasound measurements of skin thickness.
CONCLUSION
Morphea is a difficult-to-treat dermatosis, with most patients having a partial clinical response and a high recurrence rate. Overall, the median time to achieve a partial to excellent clinical improvement was 2 years. UVA1 phototherapy combined with systemic treatment was found to be a worthy option for patients.
